EpCAM as a Novel Biomarker for Survivals in Prostate Cancer Patients

EpCAM as a Novel Biomarker for Survivals in Prostate Cancer Patients

Background: Due to the insufficient understanding of the biological mechanisms, the improvement of therapeutic effects of prostate cancer (PCa) is limited. There is an urgent need to find the molecular mechanisms and underlying PCa to improve its early diagnosis, treatment, and prognosis.Methods: Th...

Full description

Bibliographic Details
Main Authors: Yang Liao, Mingxin Wu, Yingjie Jia, Ruiyu Mou, Xiaojiang Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
EpCAM
ceRNA network
prognosis
immune infiltration
prostate cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2022.843604/full

Similar Items

Similar Items